122-LB: Impact of Flash Glucose Monitoring on Behavior Modification, Quality of Life, and Treatment Satisfaction in Noninsulin Treated Patients with Type 2 Diabetes

Abstract

Introduction: CGM's have shown efficacy in the management of patients with T1D and T2D on multiple daily injections (MDI) and insulin pumps as a way to adjust insulin dosing. However, the benefit of CGM could extend beyond the dosing of insulin and has the potential to encourage lifestyle modification in non-insulin treated patients with type 2 diabetes. Methods: This prospective study included flash glucose monitoring-naive adult patients with T2D with and A1c >7% and <9%. Participants were allowed any combination of oral antidiabetic medications and glucagon-like peptide 1 (GLP-1) injections. Participants received study provided Abbott Freestyle Libre for 12 weeks. HbA1c and weight were measured, and the Diabetes Treatment Satisfaction Questionnaire (DTSQ), Audit of Diabetes Dependent Quality of Life (ADDQoL), and Food Frequency Questionnaire were all completed at baseline and 12 weeks. The Experience with Continuous Glucose Monitoring questionnaire was completed at the end of 12 weeks. Results: For participants (n=43) from one single diabetes center, HbA1c improved by 0.37% from 7.70%±0.56 (mean±SD) at baseline to 7.34%±0.57 at 12 weeks (paired t-test=3.65, p=0.0007). Glucose monitoring frequency improved, from 7.4 average number of fingersticks per week (SD: 7.74) to 4.7 flash glucose scans per day (SD: 3.09). Participants also demonstrated some glucose control with their blood sugar reading being within target range 79.44% of the time. Conclusion: The study suggests that FreeStyle Libre in insulin naïve patients with T2D can influence a decrease in A1c. Participants were more aware of their blood sugar levels while using the FreeStyle Libre and were able to achieve greater glycemic control as evidenced by their percent of time in target range. Findings from this study can be used to advocate to insurance companies to cover the Freestyle Libre in T2D patients who do not use insulin. Disclosure M. D. Simmons: None. E. J. Shiffrin: None. Funding Abbott (TJU20-27)